210 related articles for article (PubMed ID: 34208492)
1. New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
Shkundina IS; Gall AA; Dick A; Cocklin S; Mazin AV
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34208492
[TBL] [Abstract][Full Text] [Related]
2. Quinazolinone derivatives as inhibitors of homologous recombinase RAD51.
Ward A; Dong L; Harris JM; Khanna KK; Al-Ejeh F; Fairlie DP; Wiegmans AP; Liu L
Bioorg Med Chem Lett; 2017 Jul; 27(14):3096-3100. PubMed ID: 28545975
[TBL] [Abstract][Full Text] [Related]
3. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts.
Huang F; Mazin AV
PLoS One; 2014; 9(6):e100993. PubMed ID: 24971740
[TBL] [Abstract][Full Text] [Related]
4. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase.
Huang F; Mazina OM; Zentner IJ; Cocklin S; Mazin AV
J Med Chem; 2012 Apr; 55(7):3011-20. PubMed ID: 22380680
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule inhibitor of the DNA recombinase Rad51 from
Vydyam P; Dutta D; Sutram N; Bhattacharyya S; Bhattacharyya MK
J Biol Chem; 2019 May; 294(20):8171-8183. PubMed ID: 30936202
[TBL] [Abstract][Full Text] [Related]
7. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
[TBL] [Abstract][Full Text] [Related]
8. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
Roberti M; Schipani F; Bagnolini G; Milano D; Giacomini E; Falchi F; Balboni A; Manerba M; Farabegoli F; De Franco F; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Girotto S; Pellicciari R; Cavalli A
Eur J Med Chem; 2019 Mar; 165():80-92. PubMed ID: 30660828
[TBL] [Abstract][Full Text] [Related]
9. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Zhu J; Zhou L; Wu G; Konig H; Lin X; Li G; Qiu XL; Chen CF; Hu CM; Goldblatt E; Bhatia R; Chamberlin AR; Chen PL; Lee WH
EMBO Mol Med; 2013 Mar; 5(3):353-65. PubMed ID: 23341130
[TBL] [Abstract][Full Text] [Related]
10. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening.
Huang F; Motlekar NA; Burgwin CM; Napper AD; Diamond SL; Mazin AV
ACS Chem Biol; 2011 Jun; 6(6):628-35. PubMed ID: 21428443
[TBL] [Abstract][Full Text] [Related]
11. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Zhao Q; Guan J; Zhang Z; Lv J; Wang Y; Liu L; Zhou Q; Mao W
Biomed Pharmacother; 2017 Oct; 94():165-168. PubMed ID: 28759753
[TBL] [Abstract][Full Text] [Related]
14. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606
[TBL] [Abstract][Full Text] [Related]
15. Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Chao OS; Goodman OB
Mol Cancer Res; 2014 Dec; 12(12):1755-66. PubMed ID: 25127709
[TBL] [Abstract][Full Text] [Related]
16. RI-1: a chemical inhibitor of RAD51 that disrupts homologous recombination in human cells.
Budke B; Logan HL; Kalin JH; Zelivianskaia AS; Cameron McGuire W; Miller LL; Stark JM; Kozikowski AP; Bishop DK; Connell PP
Nucleic Acids Res; 2012 Aug; 40(15):7347-57. PubMed ID: 22573178
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
[TBL] [Abstract][Full Text] [Related]
18. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
[TBL] [Abstract][Full Text] [Related]
19. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
20. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.
Budke B; Kalin JH; Pawlowski M; Zelivianskaia AS; Wu M; Kozikowski AP; Connell PP
J Med Chem; 2013 Jan; 56(1):254-63. PubMed ID: 23231413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
